TP53 and neoplasm: In TME with tumor-infiltrating leukocytes, for example, it could be shown that the pharmacological activation of p53 led to an increased anti-cancerogenic immune system and tumor regression, in addition to immune activation through the induction of immune-associated cell death [48].